CRL
NYSECharles River Laboratories International Inc.
Price$167.68-2.69 (-1.58%)
01:30 PM07:45 PM
News · 26 weeks49+40%
2025-10-262026-04-19
Mix2890d
- Insider11(39%)
- Other8(29%)
- SEC Filings5(18%)
- Dividends1(4%)
- Leadership1(4%)
- Analyst1(4%)
- Other1(4%)
Latest news
25 items- PRCharles River Highlights Effectiveness of VCGs in ToxicologyPeer-reviewed evidence supports the use of Virtual Control Groups in nonclinical toxicology studies Charles River Laboratories International, Inc. (NYSE:CRL) has shared the results of a retrospective analysis in Regulatory Toxicology and Pharmacology, showing that virtual control groups (VCGs) can preserve scientific integrity while reducing reliance on animal models. The review, which looked at 20 toxicology studies that replaced concurrent control groups (CCGs) with curated VCGs, and compared the outcomes across study-level decisions and detailed endpoints. There was 100 percent concordance in the No Observed Adverse Effect Level (NOAEL) across all studies, and although there was some m
- PRCharles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference CallCharles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2026 financial results on Thursday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate th
- ANALYSTRBC Capital Mkts initiated coverage on Charles River with a new price targetRBC Capital Mkts initiated coverage of Charles River with a rating of Outperform and set a new price target of $215.00
- PRCharles River Advances Cardiovascular Health Awareness Through Support of the American Heart AssociationCharles River Laboratories International, Inc. (NYSE:CRL) today announced a collaboration with the American Heart Association, the world's leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives. "New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities," said Kristen Eisenhauer, Chief Commercial Officer, Charles River. "We are proud to support the prevention, education, and science-driven efforts needed to help sustain progress and improve cardiovascular health worldwide." Through this collaboration, Cha
- INSIDERSEC Form 3 filed by new insider Coleman Glenn3 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- PRNYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanXNYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, April 6, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on April 6thEquities rise Monday morning after a report indicates a push towards a ceasefire with Iran.The NYSE is partnering with leading AI conference HumanX at the Moscone Center in San Francisco this week and will have Ashley Mastronardi on the ground speaking to those transforming the space.James Foster, Chairman, President,
- SECSEC Form DEF 14A filed by Charles River Laboratories International Inc.DEF 14A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
- INSIDERCorporate Executive VP & COO Girshick Birgit gifted 328 shares (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERChairman, President and CEO Foster James C was granted 16,796 shares, increasing direct ownership by 6% to 279,693 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDEREVP, Corp Strategy & Develop Laplume Joseph W bought $4,364 worth of shares (25 units at $174.54), increasing direct ownership by 0.09% to 27,448 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- PRCharles River Laboratories to Present at TD Cowen and Barclays ConferencesCharles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, at 9:50 a.m. ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, at 10:00 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presenta
- SECCharles River Laboratories International Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
- PRCharles River Laboratories Provides Update on Planned Divestitures– Announces Signing of Definitive Agreements to Divest the CDMO and Cell Solutions Businesses and Certain European Discovery Services Assets – – Updates 2026 Financial Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that it has signed definitive agreements to sell certain European Discovery Services assets as well as the CDMO and Cell Solutions businesses in separate transactions. James C. Foster, Chair, President and Chief Executive Officer, said, "We are pleased to announce these planned divestitures today to demonstrate our continued progress on the actions outlined as part of the comprehensive strategic review conducted last year. We have decid
- SECCharles River Laboratories International Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
- SECSEC Form 10-K filed by Charles River Laboratories International Inc.10-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
- SECCharles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
- PRCharles River Laboratories Announces Executive AppointmentsGlenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles River as Corporate Senior Vice President and Chief Legal Officer Charles River Laboratories International, Inc. (NYSE:CRL) today announced two executive appointments: Glenn G. Coleman has been named the Company's next Chief Financial Officer and Kerry Dailey has been named to the newly-created position of Chief Legal Officer. Birgit Girshick, Corporate Executive Vice President, Chief Operating Officer and incoming Chief Executive Officer, commented, "We are very pleased to welcome Kerry Dailey and Glenn Coleman in two key executive roles, as we stre
- PRCharles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance– Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP Earnings per Share of $2.39 – – Full-Year GAAP Loss per Share of $(2.91) and Non-GAAP Earnings per Share of $10.28 – – Provides 2026 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2025 and provided guidance for 2026. For the quarter, revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.9%, and the divestiture of a small Safety Assessm
- SECSEC Form SCHEDULE 13G filed by Charles River Laboratories International Inc.SCHEDULE 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
- INSIDEREVP, Corp Strategy & Develop Laplume Joseph W was granted 5,456 shares and covered exercise/tax liability with 1,749 shares, increasing direct ownership by 16% to 27,423 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDEREVP & Chief People Officer Creamer Victoria L was granted 5,006 shares and covered exercise/tax liability with 1,296 shares, increasing direct ownership by 17% to 26,072 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERChairman, President and CEO Foster James C covered exercise/tax liability with 14,664 shares and was granted 39,031 shares, increasing direct ownership by 11% to 253,677 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERCorporate Executive VP & COO Girshick Birgit was granted 9,500 shares and covered exercise/tax liability with 3,061 shares, increasing direct ownership by 31% to 26,913 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)